Fabry

Amicus Therapeutics, Inc. (NASDAQ: FOLD) announced the path forward for U.S. regulatory approval for migalastat, including an additional trial in Fabry disease, focused on gastrointestinal (GI) symptoms. JPMorgan’s Anupama Rama maintains an Overweight rating on the company, while lowering the...